Gene expression in neoplasms of the pancreas: Applications to diagnostic pathology

Advances in Anatomic Pathology

Volumn 10, Issue 3, 2003, Pages 125-134

  Iacobuzio Donahue, Christine A ^a   Hruban, Ralph H ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Gene expression; Pancreatic cancer; Tumor marker

Indexed keywords

TUMOR MARKER;

GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METHODOLOGY; PANCREAS CARCINOMA; PANCREAS TUMOR; REVIEW;

CARCINOMA, PANCREATIC DUCTAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0642281920     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-200305000-00002     Document Type: Review

References (70)

1. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, et al. Molecular pathology of pancreatic cancer. Cancer J 2001;7:251-8.
2. Ebert M, Yokoyama M, Friess H, et al. Induction of platelet-derived growth factor A and B chains and overexpression of their receptors in human pancreatic cancer. Int J Cancer 1995;62:529-35.
3. Friess H, Yamanaka Y, Buchler M, et al. Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993;53:2704-7. (Pubitemid 23180499)
4. Su GH, Hilgers W, Shekher M, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor-suppressor gene. Cancer Res 1998;58:2339-42. (Pubitemid 28252690)
5. Lagna G, Hata A, Hemmati-Brivanlou A, et al. Partnership between DPC4 and SMAD proteins in TGF-beta signaling pathways. Nature 1996;383:832-6. (Pubitemid 26372668)
6. Hahn SA, Schutte M, Hoque ATMS, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
7. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-30. (Pubitemid 26170688)
8. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic: a new marker of DPC4 inactivation. Am J Pathol 2000;156:37-43. (Pubitemid 30644436)
9. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002-6. (Pubitemid 30207663)
10. van Heek T, Rader AE, Offerhaus GJ, et al. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol 200;117:755-65.
11. Argani P, Shaukat A, Kaushal M, et al. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer 2001;91:1332-41. (Pubitemid 32267045)
12. Tascilar M, Skinner HG, Rosty C, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001;7:4115-21. (Pubitemid 34044636)
13. +. Am J Pathol 1998;152:1501-7.
14. Wilentz RE, Goggins M, Redston M, et al. Genetic, immunohistochemical, and clinical features of medullary carcinomas of the pancreas: a newly described and characterized entity. Am J Pathol 2000;156:1641-51. (Pubitemid 30646702)
15. Lynch HT, Lynch J. Lynch syndrome: genetics, natural history, genetic counseling, and prevention. J Clin Oncol 2000;18(suppl):19S-31S.
16. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
17. Klimstra DS, Wenig BM, Heffess CS. Solid-pseudopapillary tumor of the pancreas: a typically cystic carcinoma of low malignant potential. Semin Diagn Pathol 2000;17:66-80. (Pubitemid 30132100)
18. Abraham SC, Klimstra DS, Wilentz RE, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol 200;160:1361-9.
19. Notohara K, Hamazaki S, Tsukayama C, et al. Solid-pseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and CD10. Am J Surg Pathol 2000;24:1361-71.
20. Tanaka Y, Notohara K, Kato K, et al. Usefulness of beta-catenin immunostaining for the differential diagnosis of solid-pseudopapillary neoplasm of the pancreas. Am J Surg Pathol 2002;26:818-20. (Pubitemid 34546954)
21. Velculescu VE, Zhang L, Vogelstein B, et al. Serial analysis of gene expression. Science 1995;270:484-7.
22. Shalon D, Smith SJ, Brown PO. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res 1996;6:639-45. (Pubitemid 26275868)
23. Wodicka L, Dong H, Mittmann M, et al. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 1997;15:1359-67. (Pubitemid 28022729)
24. Issaq HJ, Veenstra TD, Conrads TP, et al. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292:587-92. (Pubitemid 34681100)
25. Han H, Bearss DJ, Browne LW, et al. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002;62:2890-6. (Pubitemid 34525776)
26. Gardner-Thorpe J, Ito H, Ashley SW, et al. Differential display of expressed genes in pancreatic cancer cells. Biochem Biophys Res Commun 2002;293:391-5. (Pubitemid 34694219)
27. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, et al. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 2002;21:4587-94. (Pubitemid 34785735)
28. Crnogorac-Jurcevic T, Efthimiou E, Capelli P, et al. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001;20:7437-46. (Pubitemid 33078216)
29. Gress TM, Wallrapp C, Frohme M, et al. Identification of genes with specific expression in pancreatic cancer by cDNA representational difference analysis. Genes Chromosomes Cancer 1997;19:97-103. (Pubitemid 27231484)
30. Gress TM, Muller-Pillasch F, Geng M, et al. A pancreatic cancerspecific expression profile. Oncogene 1996;13:1819-30.
31. Geng M, Wallrapp C, Muller-Pillasch F, et al. Isolation of differentially expressed genes by combining representational difference analysis (RDA) and cDNA library arrays. Biotechniques 1998;25:434-8. (Pubitemid 28447486)
32. Geng MM, Ellenrieder V, Wallrapp C, et al. Use of representational difference analysis to study the effect of TGFβ on the expression profile of a pancreatic cancer cell line. Genes Chromosomes Cancer 1999;26:70-9. (Pubitemid 29374865)
33. Ryu B, Jones J, Blades NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by largescale serial analysis of gene expression. Cancer Res 2002;62:819-26. (Pubitemid 34126959)
34. Weber CK, Sommer G, Michl P, et al. Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology 2001;121:657-67. (Pubitemid 32822581)
35. Michl P, Buchholz M, Rolke M, et al. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 2001;121:678-84. (Pubitemid 32822583)
36. Nakatsura T, Senju S, Ito M, et al. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002;32:826-36. (Pubitemid 34257560)
37. Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol 2002;118:52-9. (Pubitemid 34734252)
38. Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002;62:1868-75. (Pubitemid 34408515)
39. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997;14:2729-33. (Pubitemid 27283112)
40. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is expressed in the vast majority of adenocarcinomas of the pancreas: identification of a new cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (in press).
41. Andrianifahanana M, Moniaux N, Schmied BM, et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 2001;7:4033-40. (Pubitemid 34044624)
42. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002;160:1239-49. (Pubitemid 34411628)
43. Argani P, Rosty C, Reiter RE, et al. Discovery of new markers of cancer through serial analysis of gene expression (SAGE): prostate stem cell antigen (PSCA) is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001;61:4320-4. (Pubitemid 32685751)
44. Conejo JR, Kleeff J, Koliopanos A, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 2000;88:12-20.
45. Rosty C, Ueki T, Argani P, et al. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol 2002;160:45-50. (Pubitemid 34052264)
46. Wallrapp C, Hahnel S, Muller-Pillasch F, et al. A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res 2000;60:2602-6. (Pubitemid 30318232)
47. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-40. (Pubitemid 26041483)
48. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998;95:1735-40. (Pubitemid 28103463)
49. McCarthy DM, Maitra A, Rader AE, et al. Utility of novel markers of pancreatic duct adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen increase specificity. Mod Pathol 2002;15:324.
50. Carraway KL, Perez A, Idris N, et al. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive. Prog Nucleic Acid Res Mol Biol 2002;71:149-85.
51. Swartz MJ, Batra SK, Varshney GC, et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol 2002;117:791-6. (Pubitemid 34457016)
52. Schafer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996;21:134-40.
53. Yamashiro S, Yamakita Y, Ono S, et al. Fascin, an actin-bundling protein, induces membrane protrusions and increases cell motility of epithelial cells. Mol Biol Cell 1998;9:993-1006. (Pubitemid 28457295)
54. Grothey A, Hashizume R, Ji H, et al. C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 2000;19:4864-75.
55. Keim V, Iovanna JL, Rohr G, et al. Characterization of a rat pancreatic secretory protein associated with pancreatitis. Gastroenterology 1991;100:775-82.
56. Zhou W, Sokoll LJ, Bruzek DJ, et al. Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev 1998;7:109-12. (Pubitemid 28109841)
57. Morino M, Yasuda T, Shirakami T, et al. HSP47 as a possible marker for malignancy of tumors in vivo. In Vivo 1994;8:285-8. (Pubitemid 24269696)
58. Sauk JJ, Coletta RD, Norris K, et al. Binding motifs of CBP2 a potential cell surface target for carcinoma cells. J Cell Biochem 2000;78:251-63. (Pubitemid 30415902)
59. Saffran DC, Raitano AB, Hubert RS, et al. AntiPSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA 2001;98:2658-63. (Pubitemid 32209538)
60. Jaffee EM, Schutte M, Gossett J, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 1998;4:194-203.
61. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-56. (Pubitemid 32063491)
62. Laderoute KR, Knapp AM, Green CJ, et al. Expression of the ATDC (ataxia telangiectasia group D-complementing) gene in A431 human squamous carcinoma cells. Int J Cancer 1996;66:772-8. (Pubitemid 26197945)
63. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-47. (Pubitemid 30626942)
64. Han JA, Park SC. Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J Cancer Res Clin Oncol 1999;125:89-95. (Pubitemid 29161460)
65. Gress TM, Muller-Pillasch F, Lerch MM, et al. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995;62:407-13.
66. Ryu B, Jones J, Hollingsworth MA, et al. Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res 2001;61:1833-8. (Pubitemid 32691994)
67. Iacobuzio-Donahue CA, Ryu B, Hruban RH, et al. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol 2002;160:91-9. (Pubitemid 34052270)
68. Tlsty TD. Stromal cells can contribute oncogenic signals. Semin Cancer Biol 2001;11:97-104. (Pubitemid 32423285)
69. Iacobuzio-Donahue CA, Argani Pedram, Hempen P, et al. The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion with implications for comparisons between tumor types. Cancer Res 2002;62:5351-7.
70. Gress TM, Menke A, Bachem M, et al. Role of extracellular matrix in pancreatic diseases. Digestion 1998;59:625-37. (Pubitemid 28510950)